Literature DB >> 11369885

Characterization and functional analysis of Serp3: a novel myxoma virus-encoded serpin involved in virulence.

Jean-Luc Guerin1, Jacqueline Gelfi1, Christelle Camus1, Maxence Delverdier1, James C Whisstock2, Marie-France Amardeihl1, Robert Py1, Stéphane Bertagnoli1, Frédérique Messud-Petit1.   

Abstract

Myxoma virus (MV), a member of the family Poxviridae, is the causative agent of myxomatosis, a fatal disease of the European rabbit. The MV genome is a linear, double-stranded DNA molecule that encodes several factors important for evasion of the host immune system. Sequencing the right-end region of the MV genome identified an 801 bp open reading frame (ORF) encoding a polypeptide that belongs to the serpin superfamily. To date, two MV-encoded serpins have been characterized: SERP-1 binds to several targets and is an anti-inflammatory molecule, whereas Serp2 is essential for virus virulence and has both anti-inflammatory and anti-apoptotic effects. Thus, Serp3 is the third MV-encoded serpin. DNA sequence analysis of Serp3 indicated a similarity to poxvirus late promoters, which was confirmed by mRNA expression analysis. Serp3 has an atypical serpin motif and has significant sequence deletions as compared to most cellular and viral serpins. However, molecular modelling studies suggested that Serp3 can retain the overall serpin fold. Insertional inactivation of the serp3 ORF led to a significant attenuation of virulence in vivo (as measured by the increase in survival of infected rabbits) and limited dissemination of the virus to secondary sites of infection. In rabbits infected with a Serp3 deletion mutant (MV-Serp3(-)), the main histopathological feature is the absence of secondary myxomas. Both wild-type MV and MV-Serp3(-) replicate at comparable levels in vivo. Serp3 may represent a significant virulence factor of MV and probably acts in synergy with other viral proteins.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11369885     DOI: 10.1099/0022-1317-82-6-1407

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  14 in total

Review 1.  The immunoregulatory properties of oncolytic myxoma virus and their implications in therapeutics.

Authors:  Jia Liu; Sonia Wennier; Grant McFadden
Journal:  Microbes Infect       Date:  2010-09-09       Impact factor: 2.700

2.  Genetic Variability of Myxoma Virus Genomes.

Authors:  Christoph Braun; Andrea Thürmer; Rolf Daniel; Anne-Kathrin Schultz; Ingo Bulla; Horst Schirrmeier; Dietmar Mayer; Andreas Neubert; Claus-Peter Czerny
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

3.  Myxoma virus leukemia-associated protein is responsible for major histocompatibility complex class I and Fas-CD95 down-regulation and defines scrapins, a new group of surface cellular receptor abductor proteins.

Authors:  Jean-Luc Guerin; Jacqueline Gelfi; Severine Boullier; Maxence Delverdier; Frederique-Anne Bellanger; Stephane Bertagnoli; Ingo Drexler; Gerd Sutter; Frederique Messud-Petit
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

4.  Comparative analysis of the complete genome sequence of the California MSW strain of myxoma virus reveals potential host adaptations.

Authors:  Peter J Kerr; Matthew B Rogers; Adam Fitch; Jay V Depasse; Isabella M Cattadori; Peter J Hudson; David C Tscharke; Edward C Holmes; Elodie Ghedin
Journal:  J Virol       Date:  2013-08-28       Impact factor: 5.103

5.  A virulence factor of myxoma virus colocalizes with NF-kappaB in the nucleus and interferes with inflammation.

Authors:  Christelle Camus-Bouclainville; Laurence Fiette; Sophie Bouchiha; Béatrice Pignolet; Dorian Counor; Cédric Filipe; Jacqueline Gelfi; Frédérique Messud-Petit
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

Review 6.  The current status and future directions of myxoma virus, a master in immune evasion.

Authors:  Bart Spiesschaert; Grant McFadden; Katleen Hermans; Hans Nauwynck; Gerlinde R Van de Walle
Journal:  Vet Res       Date:  2011-06-09       Impact factor: 3.683

7.  Genome sequence of SG33 strain and recombination between wild-type and vaccine myxoma viruses.

Authors:  Christelle Camus-Bouclainville; Magalie Gretillat; Robert Py; Jacqueline Gelfi; Jean Luc Guérin; Stéphane Bertagnoli
Journal:  Emerg Infect Dis       Date:  2011-04       Impact factor: 6.883

Review 8.  Myxoma virus and the Leporipoxviruses: an evolutionary paradigm.

Authors:  Peter J Kerr; June Liu; Isabella Cattadori; Elodie Ghedin; Andrew F Read; Edward C Holmes
Journal:  Viruses       Date:  2015-03-06       Impact factor: 5.048

Review 9.  Poxviruses Utilize Multiple Strategies to Inhibit Apoptosis.

Authors:  Daniel Brian Nichols; William De Martini; Jessica Cottrell
Journal:  Viruses       Date:  2017-08-08       Impact factor: 5.048

Review 10.  Lessons in détente or know thy host: the immunomodulatory gene products of myxoma virus.

Authors:  Martha C Zúñiga
Journal:  J Biosci       Date:  2003-04       Impact factor: 2.795

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.